Overview of Pancreatic Neuroendocrine Tumors (PNETs) and Their Types

Pancreatic neuroendocrine tumors (PNETs) represent a rare subset of pancreatic cancers, comprising approximately 1-2% of all pancreatic malignancies. They originate from the islet cells of the pancreas, which are responsible for producing hormones such as insulin, glucagon, and somatostatin. PNETs can be classified into two main categories: functional and non-functional tumors. Functional tumors actively secrete hormones, leading to specific clinical syndromes, while non-functional tumors do not produce hormones and are often asymptomatic until they reach an advanced stage.

The incidence of PNETs has been rising, likely due to advancements in imaging techniques that enable earlier detection (Bidani et al., 2025). The World Health Organization (WHO) classifies PNETs based on their differentiation, mitotic activity, and Ki-67 proliferation index, which helps in predicting their biological behavior and guiding treatment strategies (Bidani et al., 2025).

Current Surgical Strategies for PNET Management

Surgical intervention is considered the cornerstone of treatment for localized PNETs, as it offers the potential for cure. The primary surgical options include:

Enucleation: This technique is suitable for small, well-defined tumors located away from the main pancreatic ducts, typically insulinomas. It preserves surrounding pancreatic tissue and minimizes postoperative complications.
Distal Pancreatectomy: Indicated for tumors situated in the body or tail of the pancreas, this procedure involves the removal of the distal portion of the pancreas, with or without splenectomy. It is often performed for larger or symptomatic tumors.
Pancreaticoduodenectomy (Whipple Procedure): This extensive surgery is indicated for tumors located in the head of the pancreas. It involves the removal of the head of the pancreas, duodenum, gallbladder, and part of the stomach.
Total Pancreatectomy: Reserved for cases with widespread disease, this procedure removes the entire pancreas, leading to total loss of endocrine and exocrine function, necessitating lifelong management.
Conversion Surgery: In patients with initially unresectable tumors that respond to systemic therapy, conversion surgery may allow for curative resection.

Surgical strategies must be tailored based on tumor size, location, and patient health status, with multidisciplinary teams involved in decision-making (Bidani et al., 2025).

Advancements in Targeted Therapies for PNETs

Targeted therapies have revolutionized the management of advanced PNETs, particularly in patients who are not candidates for surgery. Notable advancements include:

Somatostatin Analogs (SSAs): These agents, such as octreotide and lanreotide, are effective for managing functional PNETs, controlling hormonal symptoms, and stabilizing tumor growth in non-functional PNETs by binding to somatostatin receptors on tumor cells (Bidani et al., 2025).
Tyrosine Kinase Inhibitors (TKIs): Sunitinib is a well-established TKI that targets multiple pathways involved in tumor growth and angiogenesis. It has been shown to significantly improve progression-free survival in patients with advanced PNETs (Bidani et al., 2025).
mTOR Inhibitors: Everolimus has been shown to prolong progression-free survival in patients with advanced PNETs, particularly those who are well-differentiated (Bidani et al., 2025).
Peptide Receptor Radionuclide Therapy (PRRT): This innovative therapy uses radiolabeled somatostatin analogs to deliver targeted radiation to tumor cells, significantly improving outcomes in patients with metastatic disease (Bidani et al., 2025).
Emerging Targeted Agents: Newer agents, such as cabozantinib, are under investigation for their efficacy in advanced PNETs, showing promise in overcoming resistance to existing therapies (Bidani et al., 2025).

The Role of Minimally Invasive Techniques in PNET Treatment

Minimally invasive techniques are gaining traction in the management of PNETs, offering several advantages over traditional surgical approaches:

Endoscopic Ultrasound-Guided Ablation: Techniques such as radiofrequency ablation (RFA) and microwave ablation (MWA) allow for targeted destruction of tumors with minimal damage to surrounding tissue. Studies indicate high success rates for symptom resolution in patients with functional PNETs (Bidani et al., 2025).
Trans-arterial Embolization (TAE): This procedure targets tumor blood supply to induce ischemia and necrosis, particularly useful in patients with liver metastases. It has shown promising outcomes in terms of disease control and symptom relief (Bidani et al., 2025).
Ethanol Ablation: Direct injection of ethanol into tumors has demonstrated efficacy in achieving tumor necrosis, particularly for small, localized lesions (Bidani et al., 2025).

The integration of these minimally invasive approaches into clinical practice may provide effective alternatives for patients who are not candidates for extensive surgical procedures, thereby improving quality of life and treatment outcomes.

Future Directions in PNET Research and Therapy Development

The landscape of PNET management is evolving rapidly, with ongoing research aimed at addressing current limitations and improving patient outcomes:

Personalized Medicine: The application of genomics and molecular profiling is expected to enhance treatment selection and identify patients likely to benefit from specific therapies (Bidani et al., 2025).
Combination Therapies: Ongoing trials are exploring the efficacy of combining different treatment modalities, such as targeted therapies with immunotherapy, to improve overall response rates and overcome resistance mechanisms (Bidani et al., 2025).
Longitudinal Studies: Continued assessment of treatment outcomes and patient quality of life will be critical in refining therapeutic strategies and ensuring that emerging therapies are effectively integrated into clinical practice (Bidani et al., 2025).
Patient-Centric Approaches: Emphasizing patient involvement in treatment decisions and tailoring therapies based on individual preferences and health profiles will be essential in optimizing management strategies.
Global Collaborations: Collaborative efforts among institutions worldwide can enhance research quality, ensure equitable access to advanced therapies, and improve general outcomes for patients with PNETs (Bidani et al., 2025).

FAQ Section

What are pancreatic neuroendocrine tumors (PNETs)?
PNETs are rare tumors that originate from the neuroendocrine cells of the pancreas. They can be functional, secreting hormones, or non-functional, often presenting with vague symptoms.

How are PNETs diagnosed?
Diagnosis typically involves imaging studies like CT or MRI, biochemical tests to assess hormone levels, and histological analysis through biopsy.

What is the standard treatment for localized PNETs?
The standard treatment is surgical resection, which may involve enucleation, distal pancreatectomy, or pancreaticoduodenectomy, depending on the tumor’s location and characteristics.

What are some emerging therapies for advanced PNETs?
Emerging therapies include peptide receptor radionuclide therapy (PRRT), targeted therapies like sunitinib and everolimus, and minimally invasive techniques such as ablation.

What is the prognosis for patients with PNETs?
Prognosis varies based on tumor grade and stage, with localized tumors having better outcomes compared to those that are metastatic or high-grade.

References

Bidani, K., Marinovic, A. G., Moond, V., Harne, P., & Thosani, N. (2025). Treatment of Pancreatic Neuroendocrine Tumors: Beyond Traditional Surgery and Targeted Therapy. Journal of Clinical Medicine, 14(10), 3389. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12112752/
Kell, D. B., Pretorius, E., & Zhao, H. (2025). A Direct Relationship Between ‘Blood Stasis’ and Fibrinaloid Microclots in Chronic, Inflammatory, and Vascular Diseases, and Some Traditional Natural Products Approaches to Treatment. Pharmaceuticals, 18(5), 712. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12114700/
Huang, T., Chao, J., & Lin, W. R. (2025). COVID-19 and Diabetes: Persistent Cardiovascular and Renal Risks in the Post-Pandemic Landscape. Life, 15(5), 726. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12112973/
Bekler, O., Kurtul, A., & Andò, G. (2025). Non-Dipping Pattern Is Associated with Periprocedural Myocardial Infarction in Hypertensive Patients Undergoing Elective Percutaneous Coronary Intervention. Medicina, 61(5), 794. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12112855/
Toso, A., Leoncini, M., & Maioli, M. (2025). Plasma Dickkopf-1 Levels Are Associated with Chronic Kidney Disease. Metabolites, 15(5), 300. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12112992/
Rachmadi, D., & Prabowo, A. (2025). Trends in Myocardial Infarction Morbidity and Mortality from Ischemic Heart Disease in Middle-Aged Lithuanian Population from 2000 to 2023: Data from Population-Based Kaunas Ischemic Heart Disease Register. Medicina, 61(5), 794. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12113105/